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Abstract 
The aim of the present study is to evaluate the effect of oral administration of DHEA on fertility indices in female 
rats. A total of 18 adult female rats 2.5-3.5 months old and weighting 200-250g were divided into three equal 
groups: G1-control received saline solution, G2- received 2mg DHEA /kg B.Wt orally and daily for 2 weeks prior 
to gestation. G3- received the same dose for two weeks prior and during gestation. The was a significant increase 
in fertility, gestation indeces of rats received DHEA for two weeks prior and during gestation. At the meantime, 
the gestation length, viability and lactating indeces were decreased in this group as compared with others. In 
conclusion, administration of DHEA at dose of 2 mg /kg B.Wt for 2 weeks prior to and during gestation seems to 
be safe as no abortion and fetal abnormalities were recorded. 
Keywords: DHEA, Fertility indeces, rats. 
 
1-Introduction 
5-Dehydroepiandrosterone (5-DHEA) is 19-carbon endogenous natural steroid hormone. Dehydroepiandrosterone 
(DHEA) is a hormone that is naturally made by the animal and human body. It can be made in the laboratory from 
chemicals found in wild yam and soy. However, the body cannot make DHEA from these chemicals, so simply 
eating wild yam or soy will not increase DHEA levels. DHEA and DHEAS are plentiful circulating steroids 
produced from adrenal gland and gonads. DHEA converted to testosterone or estrogen and show 90% decline by 
age (Mo et al., 2006). 
Dehydroepiandrosterone (DHEA) is used for slowing or reversing aging, improving thinking skills in 
older people, and slowing the progress of Alzheimer’s disease. Athletes and other people use DHEA to increase 
muscle mass, strength, and energy. DHEA is also used by men for erectile dysfunction (ED), and by healthy 
women and women who have low levels of certain hormones to improve well-being and sexuality (William and 
Ganong, 2005). 
It has been introduced the term of fountain of youth for DHEA (Baulieu, 1996). As it is antiaging 
hormone. There is an epidemiological evidence that have DHEA and its metabolite DHEAS levels in serum are 
associated with an increase of metabolite DHEAS levels in serum are associated with an increase of metabolic 
syndromes related to age like cardiovascular diseases, diabetes mellitus and hypertension (Thijs et al., 2003), 
(Villareal and Holloszy, 2006). All female animals are born with a definite number of eggs which deceases 
gradually with age. When the egg supply becomes very low, it is called diminished ovarian reserves (DOR) which 
is the most common causes of infertility in animals and women. However, one notable cause of DOR is decreased 
DHEA levels . Thus DHEA is used primarily to treat women with DOR which occurs either as a consequence of 
female aging or premature ovarian aging (POA). From the other hand, DHEA in used in menopause females which 
is usually associated with a sudden decline in estrogen one (Puder et al., 2000). 
We were interested to find whether DHEA administration before or during gestation has any effect on 
fertility indices. Therefore, the aim of this experiment was to evaluate the effect of 2 mg DHEA /kg body weight 
before or before and during pregnancy to female rats on fertility indices. 
 
2-Materials and Methods: 
A total of 18 adult female Albino Wistar rats weighting (200-250gm). Their ages ranged between (2.5-3.5 month) 
were divided after 2 weeks acclimatization into three equal groups as follows: G1-Received orally saline solution 
daily for two weeks prior to and during gestation time. G2-Received oral doses of 2 mg/Kg B.Wt DHEA daily for 
two weeks prior to gestation. G3-Received oral doses of 2 mg/Kg B.Wt DHEA daily for two weeks prior and 
during  gestation. 
The females of these three groups were subjected to : 
Synchronzation of estrus cycle by daily vaginal smears according to the procedure mentioned by Marcondcs et 
al., (2002). At proestrus phase, females were kept with males for mating which was confirmed after 24 hours by 
the presence of seminal plug (Donald, 1984). To confirm pregnancy, the females were subjected to daily vaginal 
smears test for five successive days where they stay in the diestrus phase. The following parameters were studied 
on pregnant female rats and newborns according to Klaassen et al (2008): 
Fertility index, Gestation index, Gestation length, Growth index, Body weight and number of newborns, Viability 
index and Lactating index. Date were expressed as mean ± SE and P-value (˂ 0.05) we considered statistically 
significant (SPSS, 2002).   
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3-Results 
3.1-Effect of DHEA on fertility and gestation indices: 
DHEA administration to rats two weeks prior and during gestation time give a clear positive result on fertility 
index. Table (1)  shows that the fertility index in this group is 100% where as that of rats received the same dose 
of DHEA for two weeks prior to gestation only (G2) was 83.33% compared to control which has fertility index of 
100%. Moreover, the infertility is (16.66%) in group of rats received 2mg/kg B.wt DHEA for two weeks prior to 
gestation (G2) as compared to (0%) for control and G3. The same table reveal that the gestation index for rats 
received DHEA before and during gestation time (G3) is 100% compared with 80% for these received DHEA for 
two weeks before gestation only (G2) and 75% for rats administered with saline solution (G1). The non-gestation % 
is 25, 20 and 0 for rats received saline, 2mg/kg B.wt DHEA two weeks before gestation and group received the 
same dose for two weeks before and during gestation time respectively. 
Table (1): Fertility, infertility, Gestation and non-gestation index (%) of adult female rats received oral daily 
doses of 2mg/ kg B.Wt DHEA two weeks before and two weeks before + during gestation time. 
parameters 
Group 
 
Fertility 
 
Infertility 
 
Gestation 
 
Non gestation 
G1 100 0 75 25 
G2 83.33 16.66 80 20 
G3 100 0 100 0 
Capital letters indicate a significant (p< 0.05) difference between groups.G1: control group received 
orally distilled water daily for two weeks prior and during gestation time, G2: received oral doses of 2 mg/Kg 
B.Wt DHEA daily for two weeks prior to gestation time, G3: received oral doses of 2 mg/Kg B.Wt DHEA daily 
for two weeks prior and during  gestation. 
 
3.2-Effect of DHEA on gestation length, body weight and growth index of newborns: 
There is a significant (p< 0.05) decrease in the gestation length of female rats received 2 mg/kg B.Wt before and 
during gestation time (G3) as compared to those received DHEA before gestation only (G2) and control groups. 
At the meantime, these rats received DHEA before gestation only (G2) have significantly (p< 0.05) shorter 
gestation length than control. Table (2) also represents the effect of DHEA administration on body weight of 
newborns. The value are (3.38 ± 0.14), (3.26 ± 0.14) and (3.04 ± 0.14) for control, G2 and G3 respectively. i.e, 
there is significant (p< 0.05) decrease in mean body weight of newborns in G2 and G3 as compared to control. 
However, the table also shows the growth index of treated and control groups and reveal a significant (p< 0.05) 
increase in rats received DHEA before and during gestation (G3) in comparison to (G2) and control. The mean 
values of growth index are (0), (3.55) and (10.05) for control, rats received DHEA before gestation only and rats 
received DHEA before + during gestation time respectively. 
Table (2): Gestation length (days) of adult rats received oral daily doses of 2mg/ kg B.Wt DHEA two weeks before 
and two weeks before + during gestation time and body weight (gm) and growth index (%) of newborns. 
Parameters  
Group 
 
Gestation length (days) Body weight of 
newborns (gm) 
Growth index (%) 
G 1 
 
21.33 ± 0.33 
A 
3.38 ± 0.140 
A 
- 
 
G 2 21.00 ± 0.00 
B 
3.26 ± 0.143 
B 
3.55 
 
G 3 
 
20.00 ± 0.57 
C 
3.04 ± 0.146 
C 
10.05 
 
Capital letters indicate a significant (p< 0.05) difference between groups.G1: control group received 
orally distilled water daily for two weeks prior and during gestation time, G2: received oral doses of 2 mg/Kg 
B.Wt DHEA daily for two weeks prior to gestation time, G3: received oral doses of 2 mg/Kg B.Wt DHEA daily 
for two weeks prior and during  gestation. 
 
3.3-Effect of  DHEA on viability and lactating indices: 
Table (3) represents the total a live newborns for the three groups of rats in this experiment. They are (13), (23) 
and (25) for control, G2 and G3 respectively. However, the viability index for rats received 2 mg/kg B.Wt for two 
weeks prior and during gestation (G3) was significantly (p< 0.05) less than rats received DHEA before gestation 
only (G2) and control groups. At the meantime, the table reveal a significant increase (p< 0.05) in the viability 
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index of newborns from rats received DHEA for two weeks before gestation time only (G2) in comparison to 
control and G3. 
The lactation index shows a significant (p< 0.05) decrease in group of rats received DHEA prior and 
during gestation time (G3) as compared to control. On the other hand, the lactating index shows higher significant 
(p< 0.05) decrease in group of rats received DHEA before gestation only (G2) as compared to control and G2. The 
values are (77.77), (50) and (73.33) for control, G2 and G3 respectively. Moreover, the lactating index for 
newborns from rats received oral administration of 2mg/hg B,wt DHEA two weeks before + during gestation (G3) 
is significant (p< 0.05) higher than those born from rats received DHEA for two weeks before gestation only (G2). 
Table (3): Viability index and Lactating index (%) of newborns from rats received oral daily doses of 2 mg/kg 
B.Wt DHEA two weeks before and two weeks before + during gestation time. 
Parameters  
Group 
Total 
newborns 
Viability index 
(%) 
a live newborns Lactating index 
(%) 
G 1 
 
13 69.23 
 
9 77.77 
 
G 2 
 
23 69.56 
 
16 50 
 
G 3 
 
25 60 
 
15 73.33 
 
Capital letters indicate a significant (p< 0.05) difference between groups.G1: control group received 
orally distilled water daily for two weeks prior and during gestation time, G2: received oral doses of 2 mg/Kg 
B.Wt DHEA daily for two weeks prior to gestation time, G3: received oral doses of 2 mg/Kg B.Wt DHEA daily 
for two weeks prior and during  gestation. 
 
4-Discussion 
In order to overcome infertility and improve the live birth rate, attention has been increased at the last few years 
to involve  DHEA (an endogenous adrenal steroid from ovarian theca cells and adrenal cortex) which is an essential 
pro-hormone in ovarian follicular steroidogenesis (Arlt, 2004). Although, the mechanism of action of DHEA on 
the ovary remains speculative, some evidence suggests the important role of androgens in normal folliculogenesis 
and female fertility (Gleicher et al., 2010). Androgens may enhance ovarian function by increasing the follicle 
recruitment (Ware, 1982).  And increasing the intra follicular androgens augments granulosa cell antimullerian 
hormone (AMH) and inhibin-B production (Andersen and Lossi, 2008). Androgen receptors (ARs) have been 
described in ovarian stroma and granulosa cells (GC) of primordial follicles, primary follicles (Otala et al., 2004). 
It has been demonstrated that ARs are crucial important for normal follicle genesis and development. 
Higher concentration of ARmRNA and AR protein were detected in pre-antral and early antral follicles which 
suggested the peak effect of androgens (Weil et al., 1998). Increased expression of AR was detected after treatment 
of DHEAS compared to cells absence of DHEAS which explained that DHEAS may exert its effect on follicles 
development through up-regulating AR (ElBeltagy et al., 2007). The expression of ARmRNA in GC and 
concentration of androgens in follicular fluid were correlated with expression of FSH receptor mRNA (Gleicher 
and Weghofer, 2008). Therefore, our results could be explained as that administration of DHEA could increase 
FSH receptors at early stages of folliculogenesis and thus it is benefit for follicle recruitment which is confirmed 
by the Signiant increase of serum FSH level after DHEA administration in our experiment (un published). 
According to the two cell-two gonadotrophin theory, androgens play an essential role in ensuring adequate 
follicular steroidogenesis. At the meantime, DHEA is a crucial precursor steroid to the sex steroid synthesis and 
is converted to androgens or estrogens. Estrogens promote ovarian follicular growth and granulosa cell 
proliferation (Sunkara et al., 2012).  Estradiol concentration shows a significant increase in rats received 2 mg/kg 
B.wt DHEA in our study (un published). 
The data results from the second experiment in this study show a 100% gestation rate for rats received 
DHEA prior and during pregnancy i.e. the miscarriage rate was 0% compared to other groups. This could be 
attributed to the beneficial role of DHEA in reducing the chromosomal abnormalities (aneuploidy) in embryos. A 
recently published study confirmed low spontaneous miscarriage rates in pregnancies conceived on DHEA 
supplementation. However, the greatest reduction in aneuploidy (22%) in embryos through preimplantation 
genetic screening (PGS) was observed with 4-12 weeks of DHEA supplementation to women prior to IVF. The 
same authors confirmed in their study that most chromosomal abnormalities in embryos result in miscarriages 
(Stmarys, 2010). 
Oral DHEA administration has been proposed to have antiaging effects and may improve ovarian 
response and pregnancy rats in women with reduced ovarian reserve (OR) during IVF (Casson et al., 2000). 
However, the  association between increasing circulating endogenous maternal testosterone levels during 
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pregnancy and a decrease in offspring birth weight and gestation length had been supported by human and animal 
data (Carlsen et al., 2006). Reported in their study an increase in circulating maternal testosterone levels from (25-
75%) at week 17 of women gestation corresponded to a decrease in birth weight of 160 g. In sheep, testosterone 
treatment to the pregnant mother during early to mid-pregnancy reduced birth weight and height in the offspring 
of other gender (Manikkam  et al., 2004). We conclude that we may want to pay more attention to DHEA levels 
in our bodies because it relates to so many aspects of overall health. 
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